Evidence map›Paper›PMID 42645164›Full record

ArticleCells2026

Nicotinamide Riboside Attenuates Cisplatin-Induced Hepatorenal Toxicity Through Restoration of NAD

Waleed Khaled Younis Albahadly, Mohammed Ibrahim Rasool, Haider Falih Shamikh Al-Saedi, Zahraa Abed Al-Kareem, Samer Ali Hasan, Mohammed Abdulaali Sahib, Meeqaat H ALtrufi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cells, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Waleed Khaled Younis AlbahadlyDepartment of Pharmacology and Toxicology, College of Pharmacy, University of Kerbala, Karbala 56001, Iraq.
Mohammed Ibrahim RasoolDepartment of Pharmacology and Toxicology, College of Pharmacy, University of Kerbala, Karbala 56001, Iraq.ORCID 0000-0003-0992-320X
Haider Falih Shamikh Al-SaediDepartment of Pharmacology and Toxicology, College of Pharmacy, University of Al-Ameed, Karbala 56001, Iraq.ORCID 0000-0003-0862-9543
Zahraa Abed Al-KareemDepartment of Pharmacology and Toxicology, College of Pharmacy, University of Kerbala, Karbala 56001, Iraq.
Samer Ali HasanDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Kufa, Najaf 54001, Iraq.ORCID 0000-0001-8495-3682
Mohammed Abdulaali SahibDepartment of Pharmaceutical Chemistry, College of Pharmacy, University of Kerbala, Karbala 56001, Iraq.ORCID 0009-0006-9992-5653
Meeqaat H ALtrufiDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Ahl Al Bayt University Kerbala, Karbala 56001, Iraq.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCisplatin is a widely used chemotherapeutic agent whose clinical application is often limited by severe hepatorenal toxicity associated with oxidative stress and cellular injury. Nicotinamide riboside (NR), a natural precursor of nicotinamide adenine dinucleotide (NAD+), has emerged as a promising cytoprotective compound with antioxidant and metabolic regulatory properties. This study investigated the protective effects of NR against cisplatin-induced hepatorenal toxicity and explored its potential mechanisms of action.

methodsThirty-six adult male Wistar rats were randomly assigned to four groups (

resultsCisplatin administration induced marked hepatorenal injury, evidenced by significant elevations in serum KIM-1 (395.27 vs. 116.04 ng/mL), urea (71.16 vs. 21.33 mg/dL), creatinine (3.49 vs. 0.26 mg/dL), AST (325.83 vs. 95.16 U/L), and ALT (102.83 vs. 45.50 U/L), accompanied by dyslipidemia, oxidative stress, and severe histopathological alterations. NR treatment significantly attenuated these changes, reducing KIM-1, urea, creatinine, AST, and ALT by 55.5%, 47.8%, 48.1%, 55.4%, and 33.5%, respectively, compared with the cisplatin group. NR also improved antioxidant status by increasing GSH and SOD levels while reducing MDA and NO concentrations. Hepatic NAD

conclusionsNicotinamide riboside exerts protective effects against cisplatin-induced hepatorenal toxicity that are mechanistically linked to activation of the Nrf2/NQO1 antioxidant pathway and restoration of hepatic NAD

Indexed as

AntioxidantsCisplatinHomeostasisKidneyLiverNADNAD(P)H Dehydrogenase (Quinone)NF-E2-Related Factor 2NiacinamidePyridinium CompoundsAnimalsMaleOxidative StressRatsRats, WistarSignal TransductionAntioxidantsCisplatinNADNAD(P)H Dehydrogenase (Quinone)NF-E2-Related Factor 2Niacinamidenicotinamide-beta-ribosideNQO1 protein, ratPyridinium Compoundsantioxidant responsecisplatingene expressionhepatorenal toxicityhistopathologynicotinamide ribosideNQO1Nrf2oxidative stress

Identifiers

PMID42645164
PMCPMC13511021

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.